Linked Life Data

16840188

Source:http://linkedlifedata.com/resource/pubmed/id/16840188

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2006-7-14
pubmed:abstractText
Bevacizumab is a humanized monoclonal antibody directed against vascular endothelial growth factor (VEGF-A). Non-Hodgkin's lymphoma patients with high serum VEGF levels have an inferior survival compared to patients with low VEGF levels. Bevacizumab was administered through a central line at 15 mg kg(-1) IV on day 1 followed by rituximab (R) and CHOP on day 2 for cycle 1 and day 1 for cycles 2 - 8. Serum levels of bevacizumab and R were measured at specified time points to assess pharmacokinetics (PK). Plasma and urine samples were also analysed for VEGF. Tumor samples were stained for VEGF, CD31 and factor VIII by immunohistochemistry. Thirteen patients with newly-diagnosed DLBCL received a total of 88 cycles (range 2 - 8, median 7). Best response included five CR, six PR, one SD and one PD with an overall response rate of 85% and complete response rate of 38%. The 12-month PFS is 77% and a median follow-up of 16.9 months for the surviving patients. All tumor samples stained strongly positive for VEGF and there was a marginal association between baseline plasma VEGF and response (p = 0.04). Patients with higher plasma VEGF levels were generally younger and had bulky disease. Micro-vessel density did not correlate with presenting disease characteristics, VEGF expression or response. The PK of bevacizumab and rituximab were not influenced by combined treatment. In this patient population, treatment with RA-CHOP did not result in any episodes of grade 3 or 4 proteinuria, heart failure or hemorrhage. The RA-CHOP combination was generally well tolerated and safe.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1042-8194
pubmed:author
pubmed:issnType
Print
pubmed:volume
47
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
998-1005
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:16840188-Adult, pubmed-meshheading:16840188-Angiogenesis Inhibitors, pubmed-meshheading:16840188-Antibodies, Monoclonal, pubmed-meshheading:16840188-Antibodies, Monoclonal, Humanized, pubmed-meshheading:16840188-Antibodies, Monoclonal, Murine-Derived, pubmed-meshheading:16840188-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:16840188-Cohort Studies, pubmed-meshheading:16840188-Cyclophosphamide, pubmed-meshheading:16840188-Doxorubicin, pubmed-meshheading:16840188-Female, pubmed-meshheading:16840188-Humans, pubmed-meshheading:16840188-Lymphoma, B-Cell, pubmed-meshheading:16840188-Lymphoma, Large B-Cell, Diffuse, pubmed-meshheading:16840188-Male, pubmed-meshheading:16840188-Middle Aged, pubmed-meshheading:16840188-Neovascularization, Pathologic, pubmed-meshheading:16840188-Prednisone, pubmed-meshheading:16840188-Tumor Markers, Biological, pubmed-meshheading:16840188-Vincristine
pubmed:year
2006
pubmed:articleTitle
Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis.
pubmed:affiliation
Department of Medicine (Oncology), Stanford University, CA, USA. kganjoo@stanford.edu
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't